Prot #CLTR0310-301: PHASE III, MULTICENTER, RANDOMIZED, TRIAL OF CPX-351 (CYTARABINE: DAUNORUBICIN) LIPOSOME INJECTION VERSUS CYTARABINE AND DAUNORUBICIN IN PATIENTS 60-75 YEARS OF AGE WITH UNTREATED HIGH RISK (SECONDARY) AML

Project: Research project

Project Details

StatusActive
Effective start/end date2/19/132/19/21

Funding

  • Celator Pharmaceuticals, Inc. (Prot #CLTR0310-301)